Clinical trials: Crohn Disease
Inflammatory Bowel Disease (IBD), Ulcerative Colitis
A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
This is a non-interventional, retrospective study of adult participants with IBD. IBD consists of either ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT05596422
- Where
- 4 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- Takeda
Crohn Disease, Ulcerative Colitis
The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
A multi-center observational study based at referral centers and community hospitals within the US. Patients' blood will be collected at enrollment for testing with PredictSURE IBD™, which will occur at a later date.
- Conditions
- Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
- Trial name
- NCT03952364
- Testing
- PredictSURE IBD™
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- PredictImmune Ltd
Crohn's Disease
Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
This study of Humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with Crohn's disease who are receiving Humira for a long…
- Trial name
- NCT01464333
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Fibrostenotic Crohn's Disease
A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical…
- Trial name
- NCT07118878
- Testing
- AGMB-129
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Agomab Spain S.L.U.
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Crohn's Disease, Rheumatoid Arthritis
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
For public health purposes disability is becoming increasingly important as an outcome measure. Despite this, there are few data on the effectiveness of adalimumab on disability outcomes in patients with immune-mediated…
- Conditions
- Crohn's Disease, Rheumatoid Arthritis, Psoriasis
- Trial name
- VITALITY (NCT02451839)
- Volunteers
- 168 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylitis
bIosimilar of aDalimumab, an European evAluation
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn Disease
- Trial name
- IDEA (NCT05190484)
- Volunteers
- 1,050 people
- Sponsor
- Fresenius Kabi
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Crohn's Disease, Obesity or Overweight
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and…
- Trial name
- COMMIT-CD (NCT06937099)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 183 sites in United States, Austria and 20 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study of Abatacept in Patients With Active Crohn's Disease
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00406653
- Testing
- abatacept
- Where
- 101 sites in United States, Australia and 15 more
- Volunteers
- 451 people
- Sponsor
- Bristol-Myers Squibb
Crohn Disease
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
Bio-naive participants are defined as the participants who previously have not received any biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the endoscopic remission at week 24 among…
- Trial name
- NCT06082986
- Testing
- Ustekinumab
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Ulcerative Colitis, Crohn's Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase…
- Trial name
- NCT03650413
- Testing
- UTTR1147A
- Where
- 57 sites in United States, Bulgaria and 12 more
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.
Crohn's Disease
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
- Trial name
- NCT02531113
- Testing
- RPC1063
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 69 people
- Sponsor
- Celgene
Crohn's Disease, Ulcerative Colitis
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
- Trial name
- NCT03283085
- Testing
- 25 mg Ontamalimab, 75 mg Ontamalimab
- Where
- 419 sites in United States, Argentina and 35 more
- Volunteers
- 557 people
- Sponsor
- Shire
Inflammatory Bowel Diseases
ImmuneSense™ IBD Study
This study will enroll adult and pediatric participants across 3 phases: Research phase, Clinical Validation (CV) and Analytical Validation (AV) phase.
- Trial name
- NCT05769829
- Where
- 6 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
Colitis, Ulcerative, Crohn Disease
A Study of Vedolizumab in Adults in Real-World Practice
Vedolizumab is a medicine that is currently prescribed for adults with moderately to severely active ulcerative colitis or Crohn's disease.
- Trial name
- NCT04872491
- Where
- 40 sites in China
- Volunteers
- 500 people
- Sponsor
- Takeda
Moderate to Severe Crohn's Disease
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
- Trial name
- AMALTHEA (NCT06450197)
- Testing
- AZD7798
- Where
- 116 sites in United States, Argentina and 24 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Crohn Disease
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
- Trial name
- NCT03808103
- Testing
- Bacteriophage preparation
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Intralytix, Inc.
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240108
- Testing
- Rifaximin EIR
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Bausch Health Americas, Inc.
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.